Retracted: Increased HO‐1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: Obese leptin deficient (ob/ob) mice are a model of adiposity that displays increased levels of fat, glucose, and liver lipids. Our hypothesis is that HO‐1 overexpression ameliorates fatty liver development. Methods: Obese mice were administered cobalt protoporphyrin (CoPP) and stannic mesoporphyrin (SnMP) for 6 weeks. Heme, HO‐1, HO activity, PGC1α, FGF21, glycogen content, and lipogenesis were assessed. Results: CoPP administration increased hepatic HO‐1 protein levels and HO activity, decreased hepatic heme, body weight gain, glucose levels, and resulted in decreased steatosis. Increased levels of HO‐1 produced a decrease in lipid droplet size, Fatty acid synthase (FAS) levels involving recruitment of FGF21, PPARα, and Glut 1. These beneficial effects were reversed by inhibition of HO activity. Conclusion: Increased levels of HO‐1 and HO activity reduced the levels of obesity by reducing hepatic heme and lipid accumulation. These changes were manifested by decreases in cellular heme, increases in FGF21, glycogen content, and fatty liver. The beneficial effect of HO‐1 induction results from an increase in PPARα and FGF21 levels and a decrease in PGC1α, levels they were reversed by SnMP. Low levels of HO‐1 and HO activity are responsible for fatty liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115 · cited 5×
“HO-1 has been implicated as a major regulator of several epigenetic signaling pathways by limiting the amount of heme and/or CO, which strongly binds to heme proteins CYP450, 4A10, 2E,1 prevents NAFLD fibrosis, and decreases iNOS or COX-2 (36) resulting in the suppression of inflammatory cytokines (4).”
InfluentialSelf-citationObesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830
Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704 · cited 1×
“FGF21 regulates hepatic carbohydrate and glycogen content and is PGC-1a expression dependent (16).”
BackgroundPro-oxidant and cytotoxic effects of circulating heme
Jeney, V., Balla, J., Yachie, A., Varga, Z., Vercellotti, G. M., Eaton, J. W., & Balla, G. (2002) · Blood · doi:10.1182/blood.v100.3.879 · Cited by 633 · cited 2×
“A decrease in both human and rodent HO-1 levels caused severe oxidative stress due a concomitant increase in cellular heme iron levels (24,25), (reviewed in Ref.”
BackgroundYoon, M. J., Lee, G. Y., Chung, J.-J., Ahn, Y. H., Hong, S. H., & Kim, J. B. (2006) · Diabetes · doi:10.2337/db05-1322 · Cited by 546 · cited 1×
“Phosphorylation of AMPK is elevated in the presence of increased PPARa activity (38).”
BackgroundFinegold, A. A., Shatwell, K. P., Segal, A. W., Klausner, R. D., & Dancis, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31021 · Cited by 213 · cited 4×
“Increases in HO-1 expression and HO activity decreased the mitochondrial release of ROS via an increase in superoxide dismutase, catalase, and the mitochondrial signaling pathway (13).”
BackgroundInfluentialCao, J., Peterson, S. J., Sodhi, K., Vanella, L., Barbagallo, I., Rodella, L. F., Schwartzman, M. L., Abraham, N. G., & Kappas, A. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.193805 · Cited by 94
Self-citation
Cited by
Bilirubin in the Liver–Gut Signaling Axis
Hamoud, A.-R., Weaver, L., Stec, D. E., & Hinds, T. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.01.002 · Cited by 254
Self-citationA Novel Perspective on the Biology of Bilirubin in Health and Disease
Gazzin, S., Vitek, L., Watchko, J., Shapiro, S. M., & Tiribelli, C. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.004 · Cited by 216
“In obese mice, increased production of BLB activates peroxisome proliferator-activated receptor (PPAR)-/, fibroblast growth factor (FGF)-21 and glucose transporter (Glut)-1, resulting in reduced lipid droplet size, fatty acid synthase levels, body weight, and blood glucose [51].”
BackgroundBilirubin Binding to PPARα Inhibits Lipid Accumulation
Stec, D. E., John, K., Trabbic, C. J., Luniwal, A., Hankins, M. W., Baum, J., & Hinds, T. D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153427 · Cited by 191
“However, both biliverdin and fenofibrate significantly (p 0.001) increased expression of CPT1.”
BackgroundInfluentialSelf-citationAdeosun, S. O., Gordon, D. M., Weeks, M. F., Moore, K. H., Hall, J. E., Hinds, T. D., & Stec, D. E. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00495.2017 · Cited by 73
“We have shown that mice with hyperbilirubinemia had reduced hepatic fat accumulation (18, 19).”
BackgroundSelf-citationStec, D. E., Gordon, D. M., Nestor-Kalinoski, A. L., Donald, M. C., Mitchell, Z. L., Creeden, J. F., & Hinds, T. D. (2020) · Biomolecules · doi:10.3390/biom10030387 · Cited by 50
“Activation of heme oxygenase-1 (HO-1) has beneficial effects to prevent fatty liver disease [15,31,70,71], which is most likely mediated by BVRA production of bilirubin [15,21,28,72].”
BackgroundSelf-citation
Metadata
- Authors
- Hinds, T. D., Sodhi, K., Meadows, C., Fedorova, L., Puri, N., Kim, D. H., Peterson, S. J., Shapiro, J., Abraham, N. G., & Kappas, A.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2013-12-02
- Volume
- 22
- Issue
- 3
- Pages
- 705-712
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W1881100739
- Cited by
- 99
- References
- 7
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.